Does complement activation control 'tissue trafficking' by C3a and C5a anaphylotoxin generation?
Foreman
K E
KE
Department of Pathology, University of Michigan, Ann Arbor, USA.
Glovsky
M M
MM
Warner
R L
RL
Horvath
S J
SJ
Ward
P A
PA
D018821:CD18 Antigens / Q000096:biosynthesis; D002448:Cell Adhesion / Q000187:drug effects; D002478:Cells, Cultured; D003167:Complement Activation; D015926:Complement C3a / Q000096:biosynthesis* / Q000494:pharmacology; D015936:Complement C5a / Q000096:biosynthesis* / Q000494:pharmacology; D004730:Endothelium, Vascular / Q000166:cytology / Q000187:drug effects; D006801:Humans; D016177:Macrophage-1 Antigen / Q000096:biosynthesis; D009504:Neutrophils / Q000187:drug effects; D011994:Recombinant Proteins / Q000494:pharmacology; D014471:Umbilical Veins; D015854:Up-Regulation / Q000187:drug effects
D018821:CD18 Antigens; D016177:Macrophage-1 Antigen; D011994:Recombinant Proteins; D015926:Complement C3a; D015936:Complement C5a